chris

Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of …

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease) Read More »

TAIPEI, March 14, 2023 /PRNewswire/ — AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European Union, Great Britain, and Israel for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease. Under the …

Yahoo Finance: AnnJi Pharmaceutical Announced Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Kennedy’s Disease Treatment Read More »

First-In-Patient Trial of a Drug to Treat Kennedy’s Disease First-In-Patient Trial of a Drug to Treat Kennedy’s Disease AnnJi Pharmaceutical Co., Ltd. has launched a first-in-patient Phase 1/2a study of AJ201, a curcumin-based compound, to evaluate its safety, tolerability, and related biochemical and pharmacological activities in Kennedy’s Disease patients. The study will be conducted at …

First-In-Patient Trial of a Drug to Treat Kennedy’s Disease Read More »

AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European Union, Great Britain, and Israel for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease. Under the terms of the license agreement, AnnJi …

AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy’s Disease Read More »

AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapy MIAMI, March 02, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the …

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy Read More »

On December 3rd,2022, AnnJi received  “The National Innovation Award” from the Institute for Biotechnology and Medicine Industry of Taiwan for its new drug development project, AJ201, a Phase 2 stage Nrf2 activator for the treatment of Kennedy’s disease. AnnJi is the only small molecule new drug company among the awardees. Dr. Wendy Huang, the Chair …

AnnJi’s AJ201 Received The National Innovation Award of 2022 Read More »

Dr. Yiumo Michael Chan, VP of Research and Translational Medicine from AnnJi Pharmaceuticals (AnnJi) was invited to speak at 2022 Kennedy’s Disease Association Conference (November 9-11, 2022) held in San Diego, California to introduce the first-in-patient study of AJ201 for the treatment of Kennedy’s Disease, or SBMA. Dr. Chan’s presentation was eagerly anticipated and well …

AnnJi Pharmaceutical Announced Its First-in-Patient Clinical Study of AJ201 for Treatment of SBMA at Kennedy’s Disease Association Annual Conference Read More »

2022 Interdisciplinary Neuroscience Congress organized by Taiwan Neuroscience Alliance (TNA) was held in Linkou Chang Gung Medical Foundation, Taiwan, from September 2 to 4. TNA is gathered 16 neuroscience-related societies, ranging from basic to clinical neuroscience, from computational to cognitive neuroscience, and from technology to therapeutic advances. Its Award Committee awarded the AnnJi representative Dr. …

AnnJi Scientist Won The Best Oral Presentation in The “2022 Interdisciplinary Neuroscience Congress” Read More »

AnnJi Pharmaceutical Co., Ltd. is launching the first-in-patient study of AJ201 for the treatment of SBMA (Spinal and Bulbar Muscular Atrophy, or Kennedy’s Disease) to evaluate the safety and clinical responses of AJ201. This study will take place in six clinical sites across the United States and patient recruitment is expected to begin in late …

AnnJi Pharmaceutical Co., Ltd. Announces the Initiation of a Clinical Study of AJ201 for the Treatment of SBMA Read More »

Dr. Cheng-Lung (Andy) Chen presented a scientific poster in “2022 Annual Meeting of Taiwan Neurological Society” titled “A Phase 1, Randomized, Double Blind, Placebo Controlled Study, To Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of AJ201 in Healthy Volunteers”, in which pharmacological safety and pharmacokinetics (PK) of AJ201 in …

AnnJi Pharmaceutical Presented the Results of AJ201 Phase I Clinical Study in 2022 Annual Meeting of Taiwan Neurological Society Read More »